Thursday, May 23, 2019 - Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Vadim Gladyshev, Ph.D., Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.
The rate of aging varies significantly across species and cell types and is further modified by genetic and environmental factors. This diversity sheds light on general principles and mechanisms of lifespan control, and they can be studied by applying comparative genomics approaches to short- and long-lived species and carrying out analyses across panels of mammals.
The scientists at the Dr. Gladyshev's lab sequenced the genomes of several mammals with exceptional lifespan and identified genes that may contribute to their longevity. They also carried out analyses of gene expression, metabolites and elements across large panels of mammals.
The presentation will focus on the results of these studies, pointing to both lineage-specific and common adaptations to longevity and identifying signatures, that characterize species lifespan and the effects of interventions that adjust lifespan within species. Using these signatures, one may identify new pharmacological, dietary and genetic interventions with the potential to increase lifespan. To characterize longevity interventions in mice, blood and multi-tissue DNA methylation clocks were developed as well. Together, these genomics approaches and tools offer a platform for unbiased discovery and validation of longevity interventions in mammals.
"There will be an immediate and broad impact in the field, if an intervention is proven to extend human lifespan. Studies on model organisms can guide us in finding the best ways to extend human lifespan," said Vadim Gladyshev, Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School.
"It is a great pleasure that Professor Vadim Gladyshev is joining us in Basel. Professor Gladyshev is at the forefront of redox biology and aging, two fields that are merging in the context of healthy longevity. Recently, he has pioneered cross species investigations into aging allowing us to identify new potential targets for healthy aging. I am therefore extremely grateful that Professor Gladyshev will visit us in Basel, " said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
"Over the last 5 years, the "Aging & Drug Discovery" and "AI for Healthcare" forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Aging, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.
"The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019.
###
For further information, images or interviews, please contact:
Ola Popova ola@pharma.ai
Ola Popova ola@pharma.ai
About Vadim Gladyshev
Vadim Gladyshev is a Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, Director of the Center for Redox Medicine, and Associate Member of the Broad Institute. He obtained all his degrees from Moscow State University, followed by postdoc training at the National Institutes of Health and a first faculty position at the University of Nebraska. He seeks to understand the nature of aging and to define the principles of lifespan control. His lab applies high-throughput and computational approaches to achieve systems level understanding of the aging process and develop interventions that extend lifespan.
Official Website: https:/
About Brigham and Women's Hospital
Boston's Brigham and Women's Hospital (BWH) is an international leader in virtually every area of medicine and has been the site of pioneering breakthroughs that have improved lives around the world. A major teaching hospital of Harvard Medical School, BWH has a legacy of excellence that continues to grow year after year. BWH includes 150 outpatient practices with over 1,200 physicians. We serve patients from New England, throughout the United States, and from 120 countries around the world.
BWH is an internationally-known referral center for the most complex cases in nearly all areas of medicine. In fact, U.S. News and World Report has consistently ranked us a top hospital and among the best in specialty areas including cancer, cardiology and heart surgery, gynecology, neurology and neurosurgery, orthopedics, and rheumatology.
Official website: https:/
About Harvard Medical School
Since the School was established in 1782, faculty members have improved human health by innovating in their roles as physicians, mentors and scholars. They've piloted educational models, developed new curricula to address emerging needs in health care, and produced thousands of leaders and compassionate caregivers who are shaping the fields of science and medicine throughout the world with their expertise and passion. The mission of the school is to nurture a diverse, inclusive community dedicated to alleviating suffering and improving health and well-being for all through excellence in teaching and learning, discovery and scholarship, and service and leadership.
Official website: https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Official website: http://insilico.
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
University Website: http://introduction.
About Basel Life 2019
Aging Research for Drug Discovery Forum description
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.
Conference Official Website: https:/
No comments:
Post a Comment